Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
257 participants
INTERVENTIONAL
2013-10-15
2014-12-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
NCT02196324
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
NCT03677401
XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.
NCT00298623
Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli
NCT05287724
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica
NCT05978063
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.25 mg VPD-737
0.25 mg of VPD-737 daily by mouth for 42 days
VPD-737
NK1 Receptor Antagonist
1 mg VPD-737
1 mg VPD-737 taken daily by mouth for 42 days
VPD-737
NK1 Receptor Antagonist
5 mg VPD-737
5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
VPD-737
NK1 Receptor Antagonist
Placebo
placebo tablets to be taken daily by mouth for 42 days
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VPD-737
NK1 Receptor Antagonist
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vyne Therapeutics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward F Schnipper, MD
Role: STUDY_DIRECTOR
Acting Chief Medical Officer, Tigercat Pharma, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Dermatology Clinical Research, Inc.
Fremont, California, United States
Torrance Clinical Research Institute Inc.
Lomita, California, United States
Stanford University, Medical Dermatology
Redwood City, California, United States
UCSD Dermatology
San Diego, California, United States
The Center for Clinical and Cosmetic Research
Aventura, Florida, United States
Dermatology of Boca
Boca Raton, Florida, United States
Skin Care Research
Boca Raton, Florida, United States
Olympian Clinical Research
Tampa, Florida, United States
Advanced Medical Research, Inc.
Atlanta, Georgia, United States
Shideler Clinical Research Center
Carmel, Indiana, United States
The Indiana Clinical Trials Center, PC
Plainfield, Indiana, United States
Grekin Skin Institue
Warren, Michigan, United States
Minnesota Clinical Study Center
Fridley, Minnesota, United States
Quality Clinical Research Inc.
Omaha, Nebraska, United States
Comprehensive Clinical Research
Berlin, New Jersey, United States
The Dermatology Group, P.C.
Verona, New Jersey, United States
Skin Search of Rochester, Inc.
Rochester, New York, United States
Dermatology Consulting Services
High Point, North Carolina, United States
Baker Allergy, Asthma and Dermatology Research Center, LLC
Lake Oswego, Oregon, United States
Temple University
Philadelphia, Pennsylvania, United States
Suzanne Bruce and Associates, P.A.
Houston, Texas, United States
Pfugerville Dermatology
Pflugerville, Texas, United States
Dermatology Clinical Research Center of San Antonio
San Antonio, Texas, United States
WestEnd Dermatology Associates
Richmond, Virginia, United States
Marycliff Allergy Specialist
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yosipovitch G, Stander S, Kerby MB, Larrick JW, Perlman AJ, Schnipper EF, Zhang X, Tang JY, Luger T, Steinhoff M. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol. 2018 May;78(5):882-891.e10. doi: 10.1016/j.jaad.2018.02.030. Epub 2018 Feb 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TCP 101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.